Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

408

Participants

Timeline

Start Date

November 5, 2023

Primary Completion Date

March 31, 2025

Study Completion Date

September 30, 2025

Conditions
T2DM (Type 2 Diabetes Mellitus)
Interventions
DRUG

HTD1801

HTD1801 1000 mg administered orally BID as four capsules

DRUG

Placebo

Matching placebo administered orally BID as four capsules

Trial Locations (56)

Unknown

Xuancheng People's Hospital, Xuancheng

Beijing Pinggu Hospital, Beijing

Fuwai Hospital, CAMS & PUMC, Beijing

Peking Union Medical College Hospital, Beijing

Peking University People's Hospital, Beijing

Chongqing University Three Gorges Hospital, Chongqing

Nanfang Hospital, Southern Medical University, Guangzhou

Huizhou Municipal Central Hospital, Huizhou

Shenzhen People's Hospital, Shenzhen

Liuzhou People's Hospital, Liuzhou

Cangzhou Central Hospital, Cangzhou

Handan First Hospital, Handan

Hengshui People's Hospital (Harrison International Peace Hospital), Hengshui

Hebei Petro China Center Hospital, Langfang

The First Hospital of Hebei Medical University, Shijiazhuang

The Fourth Affiliated Hospital of Harbin Medical University, Harbin

The First Hospital of Qiqihar, Qiqihar

The Third Affiliated Hospital of Qiqihar Medical College, Qiqihar

The First Affiliated Hospital of Henan University of Science and Technology (Jinghua), Luoyang

The First Affiliated Hospital of Henan University of Science and Technology (Kaiyuan), Luoyang

The First Affiliated Hospital of Nanyang Medical College, Nanyang

Zhumadian Central Hospital, Zhumadian

Huangshi Central Hospital, Huangshi

Jingzhou Central Hospital, Jingzhou

The Central Hospital of Wuhan, Wuhan

The First People's Hospital of Changde City, Changde

Hunan Provincial People's Hospital, Changsha

Yueyang People's Hospital, Yueyang

Baotou City Central Hospital, Baotou

Inner Mongolia Autonomous Region People's Hospital, Hohhot

The First People's Hospital of Changzhou, Changzhou

Huai'an First People's Hospital, Huai'an

The Second People's Hospital of Lianyungang, Lianyungang

Nanjing Drum Tower Hospital - The Affiliated Hospital of Nanjing University Medical School, Nanjing

Nanjing First Hospital, Nanjing

Nanjing Jiangning Hospital, Nanjing

Sir Run Run Hospital Nanjing Medical University, Nanjing

The Second Affiliated Hospital of Nanjing Medical University, Nanjing

The Affiliated Hospital of Xuzhou Medical University, Xuzhou

Affiliated Hospital of Jiangsu University, Zhenjiang

Pingxiang People's Hospital, Pingxiang

The Second Norman Bethune Hospital of Jilin University, Changchun

Tonghua Central Hospital, Tonghua

Panjin Liaohe Oilfield Gem Flower Hospital, Panjin

The Sixth People's Hospital of Shenyang, Shenyang

Qinghai Provincial People's Hospital, Xining

The Second Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang

Jinan Central Hospital, Jinan

Liaocheng People's Hospital, Liaocheng

Shanghai East Hospital of Tongji University, Shanghai

The Third People's Hospital of Datong, Datong

Yuncheng Central Hospital, Yuncheng

People's Hospital of Tianjin, Tianjin

The First People's Hospital of Kashgar, Kashgar

The Second Affiliated Hospital of Kunming Medical University, Kunming

Huzhou Central Hospital, Huzhou

All Listed Sponsors
lead

HighTide Biopharma Pty Ltd

INDUSTRY

NCT06350890 - Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter